Sarepta Therapeutics Reports 16% Revenue Growth to $2.2 Billion for Fiscal Year 2025

Sarepta Therapeutics, Inc. reported a significant increase in net revenues for the fiscal year ended December 31, 2025, totaling $2.2 billion, a 16% rise from $1.9 billion in 2024. This growth was primarily driven by product sales, which reached $1.86 billion, up 4% from the previous year. Notably, the revenue from the gene therapy product ELEVIDYS increased by $77.9 million, attributed to its expanded label approval in June 2024. However, this was partially offset by higher discounts related to the Pediatric Health Services chargeback program, as ELEVIDYS no longer qualified for pediatric designation.

The company's operating loss for 2025 was $699.8 million, a stark contrast to the operating income of $218.1 million reported in 2024. This shift was largely due to a substantial increase in research and development expenses, which surged by 89% to $1.52 billion, driven by up-front and milestone payments associated with the Arrowhead Collaboration Agreement. Additionally, cost of sales rose significantly, reflecting increased write-offs of inventory not meeting quality specifications and a $165.3 million increase in inventory valuation reserves.

Sarepta's strategic restructuring plan, announced in July 2025, aimed to reduce operating expenses and align its cost structure with strategic priorities. This included a workforce reduction of approximately 36%, resulting in a restructuring charge of $42 million. The company reported a total employee count of 835 as of December 31, 2025, with 71% engaged in research and development activities. Despite these efforts, the restructuring may not yield the anticipated cost savings, and the company faces ongoing challenges in maintaining its operational efficiency.

Looking ahead, Sarepta's financial outlook remains uncertain, particularly in light of the recent suspension of shipments of ELEVIDYS to non-ambulatory patients following safety concerns. The company is also navigating the complexities of regulatory approvals and reimbursement policies, which could impact future revenue generation. As of December 31, 2025, Sarepta had $953.8 million in cash, cash equivalents, and investments, which it believes will be sufficient to fund operations for at least the next twelve months. However, the company may need to seek additional financing to support its ongoing research and development efforts and meet its financial obligations.